E-LIB Suche - Ergebnisse für: Popplewell, L.

1

DURABLES RESPONSES WITH ANTI‐CD19 ALLOGENEIC CAR T ALLO‐501..:

Locke, F. L. ; Lekakis, L. ; Eradat, H....
Hematological Oncology. 41 (2023) S2 - p. 85-86 , 2023

Link: https://doi.org/10.1002/..

2

Real‐World Early Outcomes of Axicabtagene Ciloleucel for Re..:

Jacobson, C. ; Hemmer, M. T. ; Hu, Z....
Hematological Oncology. 41 (2023) S2 - p. 375-376 , 2023

Link: https://doi.org/10.1002/..

3

Prognostic Significance of Positron Emission Tomography Del..:

Ladbury, C.J. ; Hao, C. ; Watkins, W.T....
International Journal of Radiation Oncology*Biology*Physics. 117 (2023) 2 - p. S53 , 2023

Link: https://doi.org/10.1016/..

4

PO-1171 Ten-year follow-up of tandem autologous transplanta..:

Ladbury, C. ; Rincon, A. ; Song, J....
Radiotherapy and Oncology. 170 (2022) - p. S992-S993 , 2022

Link: https://doi.org/10.1016/..

5

PHASE I STUDY OF THE CD19/CD3 HALF‐LIFE EXTENDED BITE® MOLE..:

Mead, M. D. ; Popplewell, L. L. ; Subklewe, M....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

6

EFFICACY AND SAFETY OF TISAGENLECLEUCEL (TISA‐CEL) IN ADULT..:

Schuster, S. J. ; Dickinson, M. ; Dreyling, M....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

7

THE COMBINATION OF VENETOCLAX, LENALIDOMIDE AND RITUXIMAB I..:

Phillips, T. J. ; Bond, D. ; Devata, S....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

8

PATIENT‐REPORTED QUALITY OF LIFE (QOL) FOLLOWING TISAGENLEC..:

Fowler, N. H. ; Dickinson, M. ; Martinez‐Lopez, J....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

9

THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 + RITUXIMAB ..:

Advani, R. ; Bartlett, N.L. ; Smith, S.M....
Hematological Oncology. 37 (2019) S2 - p. 89-90 , 2019

Link: https://doi.org/10.1002/..

10

MDS AS A CAUSE FOR PROLONGED HEMATOLOGIC TOXICITY AFTER TRE..:

Shouse, G.P. ; Xue, T. ; Herrera, A....
Hematological Oncology. 37 (2019) S2 - p. 507-508 , 2019

Link: https://doi.org/10.1002/..

11

PRELIMINARY RESULTS OF A PHASE 1 DOSE ESCALATION STUDY OF T..:

Molina, A. ; Shah, N. ; Krishnan, A.Y....
Hematological Oncology. 37 (2019) S2 - p. 324-325 , 2019

Link: https://doi.org/10.1002/..

12

SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB IN COMBINATION..:

Palomba, M.L. ; Cartron, G. ; Popplewell, L....
Hematological Oncology. 37 (2019) S2 - p. 517-519 , 2019

Link: https://doi.org/10.1002/..

13

A FIRST‐IN‐HUMAN STUDY OF A HALF‐LIFE EXTENDED CD19‐TARGETI..:

Popplewell, L. ; Verhoef, G. ; Kuruvilla, J....
Hematological Oncology. 37 (2019) S2 - p. 566-567 , 2019

Link: https://doi.org/10.1002/..

14

ELARA: A PHASE 2 TRIAL INVESTIGATING THE EFFICACY AND SAFET..:

Dickinson, M. ; Popplewell, L. ; Kolstad, A....
Hematological Oncology. 37 (2019) S2 - p. 559-560 , 2019

Link: https://doi.org/10.1002/..

15

PET‐ADAPTED NIVOLUMAB +/‐ ICE AS INITIAL SALVAGE THERAPY IN..:

Herrera, A.F. ; Chen, R. ; Palmer, J....
Hematological Oncology. 37 (2019) S2 - p. 293-293 , 2019

Link: https://doi.org/10.1002/..